Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CG53135-05, velafermin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CG53135-05, velafermin | DRUG | - |
Inclusion Criteria: * Male or female patients ages \> 18 yrs * Patients undergoing high dose chemotherapy with or without radiation therapy treatment as conditioning for autologous hematopoietic stem cell transplantation. The conditioning regimens include at least one of the following: high dose me...
CG53135-05, also known as velafermin, is an investigational small molecule being studied for the prevention of oral mucositis, a form of stomatitis, in patients receiving bone marrow transplant. It is in Phase 2 clinical development and is not yet approved by the FDA.
CG53135-05, or velafermin, is a small molecule being developed by Celldex Therapeutics. Its specific molecular target has not been disclosed in available information. It is being studied for its potential to prevent oral mucositis in patients undergoing bone marrow transplantation.
CG53135-05, also known as velafermin, is being developed by Celldex Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker CLDX. The company is conducting clinical research to evaluate the drug's safety and efficacy in preventing oral mucositis.
CG53135-05, or velafermin, is in Phase 2 clinical development. It is an investigational drug being studied for the prevention of oral mucositis in patients receiving bone marrow transplant. It has not been approved by the FDA and remains in clinical trials.
CG53135-05, or velafermin, has one completed Phase 2 clinical trial, NCT00104065, which evaluated its safety and efficacy in preventing oral mucositis in patients receiving bone marrow transplant. The trial was conducted in the United States and enrolled adults aged 18 years and older.
Yes, CG53135-05 is also known as velafermin. Both names refer to the same investigational small molecule being developed by Celldex Therapeutics for the prevention of oral mucositis in patients undergoing bone marrow transplantation.